Previous 10 | Next 10 |
2023-05-11 05:56:21 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of H. Lundbeck ( OTCPK:HLBBF ) ( OTCPK:HLUBF ) and Otsuka's ( OTCPK:OTSKY ) ( OTCPK:OTSKF ) medicine Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzh...
2023-05-09 10:06:56 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q1 GAAP EPS of -$0.28 beats by $0.06 . For further details see: Acumen Pharmaceuticals GAAP EPS of -$0.28 beats by $0.06
Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023 Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support c...
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, ann...
2023-05-03 15:37:28 ET Eli Lilly ( NYSE: LLY ) added ~7% to reach a new 52-week high Wednesday after the company reported early Phase 3 data for its anti-amyloid agent donanemab in Alzheimer's disease, sparking sharp gains among rival drug developers. Notable gainers include...
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligom...
Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s disease Results provide evidence that oligomer size may influence neuronal binding and detecti...
2023-03-27 11:06:58 ET The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Acumen Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-27 11:05:19 ET Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Conference Call March 27, 2023, 08:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer M...
2023-03-27 07:04:55 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): FY GAAP EPS of -$1.06 misses by $0.08 . Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expected to be sufficient to support clinical and operational go...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...